Le projet de l'équipe est d’identifier de nouvelles protéines et de nouveaux mécanismes impliqués dans le trafic neuronal de récepteurs, dans le but de caractériser de nouvelles cibles thérapeutiques dans le domaine de la dépression, la schizophrénie et d’autres pathologies neuronales et psychiatriques.
Mesencephalic dopaminergic neurons project towards various brain regions, including the striatum and the prefrontal cortex.
Our team carries out preclinical studies to better understand psychiatric diseases and to discover innovative therapies. We develop animal models and characterize synaptic targets which play a role in neurotransmission (mostly neurotransmitter transporters). This work is also carried out in humans using genetic and anatomical approaches, specifically focusing on autism and mental retardation.
Over the past 4 years, we have been studying psychiatric disorders and addictions that are prevalent and have a high social cost. We use magnetic resonance imaging and positron emission tomography to capture brain images in severely impaired patients and to assess the effects of treatment on brain function. We are based in the Service Hospitalier Frédéric Joliot (SHFJ), Orsay. We also collaborate with a network of psychiatrists within the Paris area and collaborate on large data sets with North Europe research teams.